OSCR

Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy.

Overview

Authors: Brandon L. McClellan1,2, Jorge A. Peña Agudelo1,2, Anzar A. Mujeeb1,2, Ali A. Dabaja1,2, Ziwen Zhu1,2, Sadhakshi Raghuram1,2, Maria Luisa Varela1,2, Claire Tronrud1,2, Kaushik Banerjee1,2, Abraham Wei1,2, Cecilia Calatroni1,2, Lucia H. Zhang1,2, Lissa Cruz Romero1,2, Paul Oh1,2, Mahmoud S. Alghamri1,2, Andrew Robbins1,2, Matthew Perricone3, Ying Wang4,5, Brian Shay4,5, Peter Sajjakulnukit3, Costas A. Lyssiotis3,6,7, Joshua D. Welch8,9, Anna Schwendeman4,5,10, Pedro R. Lowenstein1,2,7, Maria G. Castro1,2,7
ORCID iDs: Maria Luisa Varela, Andrew Robbins, Costas A. Lyssiotis, Maria G. Castro
  1. Department of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA
  2. Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
  3. Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA
  4. College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA
  5. Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA
  6. Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109, USA
  7. Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
  8. Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA
  9. Department of Computer Science and Engineering, University of Michigan, Ann Arbor, MI 48109, USA
  10. Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA
Institutions: University of Michigan (United States); Michigan Medicine (United States); U-M Rogel Cancer Center (United States)
Journal: Molecular therapy. Oncology, volume 34, issue 2, article 201215
Dates: received 15 December 2025; accepted 17 April 2026; published online 21 April 2026
Type: Research article · Language: English
License: CC BY-NC-ND
Identifiers: DOI 10.1016/j.omton.2026.201215 · PMID 42170677 · PMCID PMC13188098 · OpenAlex W4416300629
Open access: gold, a free copy (OpenAlex)
Preprint: doi:10.1101/2025.11.11.687828
Status: code on request
Categories: other condition (population)
Methods: Evoked potentials, fMRI & imaging, Statistics
Keywords: MT: Regular Issue, immunotherapy, gene therapy, glioma, mutant IDH1, CD73, Ad-TK/Ad-Flt3L
Topic: Adenosine and Purinergic Signaling (Physiology, Biochemistry, Genetics and Molecular Biology), according to OpenAlex
Funding: NIH; National Cancer Institute (R01CA244838, R01CA248160, R01CA244931); COG Repository; Health Science Center, University of North Texas (SJGBM2); University of Minnesota, deceased; National Institute of Neurological Disorder & Stroke; NINDS (R37-NS144573–01, R01-NS122165, R01-NS122536, R01-NS124167, R01-NS122234, R01-NS127378); NCI Cancer Center (2P30CA46592); Rogel Cancer Center; Pediatric Brain Tumor Foundation; Leah’s Happy Hearts Foundation; Ian's Friends Foundation; Chad Tough Foundation; Smiles for Sophie Forever Foundation; Rackham Merit Fellowship; Rackham Graduate Student Research; Rackham Predoctoral Fellowship
Citations: not cited yet (Europe PMC); 58 references in the paper
Research resources: RRID:SCR_026557

Abstract

The abstract is not reproduced here: the paper's license (CC BY-NC-ND) does not allow it. Read it in the paper, at the publisher or on Europe PMC.

Code

The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.

Data

No dataset and no data link were found in the paper.

Code and data availability statement

The paper has a code and data availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:

  • it says that the data are available on request
  • it says that the code is available on request

Read it in the paper: doi.org/10.1016/j.omton.2026.201215.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 29 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 25 authors, 7 keywords, 17 funders, 56 references, 1 RRID.

Cite

This paper

McClellan, B. L., Peña Agudelo, J. A., Mujeeb, A. A., Dabaja, A. A., Zhu, Z., Raghuram, S., Varela, M. L., Tronrud, C., Banerjee, K., Wei, A., Calatroni, C., Zhang, L. H., Romero, L. C., Oh, P., Alghamri, M. S., Robbins, A., Perricone, M., Wang, Y., Shay, B., . . . Castro, M. G. (2026). Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy. Molecular therapy. Oncology, 34(2), 201215. https://doi.org/10.1016/j.omton.2026.201215

BibTeX

@article{mcclellan2026reprogramming,
author = {McClellan, Brandon L. and Peña Agudelo, Jorge A. and Mujeeb, Anzar A. and Dabaja, Ali A. and Zhu, Ziwen and Raghuram, Sadhakshi and Varela, Maria Luisa and Tronrud, Claire and Banerjee, Kaushik and Wei, Abraham and Calatroni, Cecilia and Zhang, Lucia H. and Romero, Lissa Cruz and Oh, Paul and Alghamri, Mahmoud S. and Robbins, Andrew and Perricone, Matthew and Wang, Ying and Shay, Brian and Sajjakulnukit, Peter and Lyssiotis, Costas A. and Welch, Joshua D. and Schwendeman, Anna and Lowenstein, Pedro R. and Castro, Maria G.},
title = {{Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy}},
journal = {Molecular therapy. Oncology},
year = {2026},
month = apr,
volume = {34},
number = {2},
pages = {201215},
publisher = {American Society of Gene \& Cell Therapy},
issn = {2950-3299},
doi = {10.1016/j.omton.2026.201215},
url = {https://doi.org/10.1016/j.omton.2026.201215},
pmid = {42170677},
pmcid = {PMC13188098}
}

RIS

TY - JOUR
AU - McClellan, Brandon L.
AU - Peña Agudelo, Jorge A.
AU - Mujeeb, Anzar A.
AU - Dabaja, Ali A.
AU - Zhu, Ziwen
AU - Raghuram, Sadhakshi
AU - Varela, Maria Luisa
AU - Tronrud, Claire
AU - Banerjee, Kaushik
AU - Wei, Abraham
AU - Calatroni, Cecilia
AU - Zhang, Lucia H.
AU - Romero, Lissa Cruz
AU - Oh, Paul
AU - Alghamri, Mahmoud S.
AU - Robbins, Andrew
AU - Perricone, Matthew
AU - Wang, Ying
AU - Shay, Brian
AU - Sajjakulnukit, Peter
AU - Lyssiotis, Costas A.
AU - Welch, Joshua D.
AU - Schwendeman, Anna
AU - Lowenstein, Pedro R.
AU - Castro, Maria G.
TI - Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy
T2 - Molecular therapy. Oncology
J2 - Mol Ther Oncol
PY - 2026
DA - 2026/04/21
VL - 34
IS - 2
SP - 201215
SN - 2950-3299
PB - American Society of Gene & Cell Therapy
DO - 10.1016/j.omton.2026.201215
UR - https://doi.org/10.1016/j.omton.2026.201215
LA - en
ER -

CSL-JSON

{
"id": "10.1016/j.omton.2026.201215",
"type": "article-journal",
"title": "Reprogramming the immune suppressive tumor microenvironment in glioma enhances the efficacy of immune-mediated gene therapy",
"container-title": "Molecular therapy. Oncology",
"author": [
{
"family": "McClellan",
"given": "Brandon L."
},
{
"family": "Peña Agudelo",
"given": "Jorge A."
},
{
"family": "Mujeeb",
"given": "Anzar A."
},
{
"family": "Dabaja",
"given": "Ali A."
},
{
"family": "Zhu",
"given": "Ziwen"
},
{
"family": "Raghuram",
"given": "Sadhakshi"
},
{
"family": "Varela",
"given": "Maria Luisa"
},
{
"family": "Tronrud",
"given": "Claire"
},
{
"family": "Banerjee",
"given": "Kaushik"
},
{
"family": "Wei",
"given": "Abraham"
},
{
"family": "Calatroni",
"given": "Cecilia"
},
{
"family": "Zhang",
"given": "Lucia H."
},
{
"family": "Romero",
"given": "Lissa Cruz"
},
{
"family": "Oh",
"given": "Paul"
},
{
"family": "Alghamri",
"given": "Mahmoud S."
},
{
"family": "Robbins",
"given": "Andrew"
},
{
"family": "Perricone",
"given": "Matthew"
},
{
"family": "Wang",
"given": "Ying"
},
{
"family": "Shay",
"given": "Brian"
},
{
"family": "Sajjakulnukit",
"given": "Peter"
},
{
"family": "Lyssiotis",
"given": "Costas A."
},
{
"family": "Welch",
"given": "Joshua D."
},
{
"family": "Schwendeman",
"given": "Anna"
},
{
"family": "Lowenstein",
"given": "Pedro R."
},
{
"family": "Castro",
"given": "Maria G."
}
],
"container-title-short": "Mol Ther Oncol",
"volume": "34",
"issue": "2",
"page": "201215",
"DOI": "10.1016/j.omton.2026.201215",
"PMID": "42170677",
"PMCID": "PMC13188098",
"ISSN": "2950-3299",
"publisher": "American Society of Gene & Cell Therapy",
"URL": "https://doi.org/10.1016/j.omton.2026.201215",
"language": "en",
"issued": {
"date-parts": [
[
2026,
4,
21
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.34133/csbj.0059
Network-Based Prediction of Oligodendroglioma Driver Gene Candidates within the Region of the 1p/19q Co-deletion Utilizing Single-Cell Transcriptomes.
Journal: Computational and structural biotechnology journal
In common: other condition, 5 references
[2] doi:10.3390/cancers18132092
TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activated Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study.
Journal: Cancers
In common: other condition, 5 references
[3] doi:10.1016/j.xcrm.2026.102682 [code]
TET CpG sequence-context-specific DNA demethylation shapes progression of IDH-mutant gliomas.
Journal: Cell reports. Medicine
In common: other condition, 4 references
[4] doi:10.1038/s43018-026-01199-y
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.
Journal: Nature cancer
In common: other condition, 3 references
[5] doi:10.1080/17501911.2026.2691031
Promoter methylation-associated brain-enriched long noncoding RNAs in glioblastoma: a multi-cohort public epigenomic re-analysis.
Journal: Epigenomics
In common: other condition, 3 references
[6] doi:10.1038/s41586-026-10612-6 [code]
Acquired genetic and cell-state changes in IDH-mutant glioma progression.
Journal: Nature
In common: other condition, 3 references
[7] doi:10.1158/2767-9764.crc-25-0579 [code]
Glioblastoma Subtypes Exhibit Distinct Migration Mechanics and Immune Responses.
Journal: Cancer research communications
In common: other condition, 2 references
[8] doi:10.1038/s41598-026-53415-5 [code]
Computational design and immunoinformatics validation of a T cell multi-epitope vaccine targeting glioblastoma stem cells.
Journal: Scientific reports
In common: other condition, 2 references
[9] doi:10.1126/sciadv.adz5324 [code]
High mannose content of mesenchymal glioblastoma correlates with hydroxyl proton transfer-weighted (HPTw) MRI as noninvasive biomarker of tumor aggressiveness.
Journal: Science advances
In common: other condition, 2 references
[10] doi:10.1021/acs.jmedchem.6c00035
The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of <i>MTAP</i>-Deleted Cancers.
Journal: Journal of medicinal chemistry
In common: other condition, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.